Emergence of Gastrointestinal Basidiobolomycosis in the United States, with a Review of Worldwide Cases

Holenarasipur R. Vikram, Jerry D. Smilack, Jonathan A Leighton, Michael D. Crowell, Giovanni De Petris

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background. We examined the epidemiology, clinical manifestations, histopathology, management, and outcomes of gastrointestinal basidiobolomycosis, an uncommon manifestation of infection caused by the fungus Basidiobolus ranarum.Methods.In this retrospective observational cohort study, cases of gastrointestinal basidiobolomycosis in the United States were identified by reviewing medical records from Mayo Clinic Hospital (Phoenix, AZ) and contacting local infectious diseases specialists, pathologists, gastroenterologists, the Arizona Department of Health Services, health departments of adjacent states, the Armed Forces Institute of Pathology, and the US Centers for Disease Control and Prevention. A comprehensive literature review identified additional cases worldwide.Results.Of 44 patients (mean age, 37 years [range, 2-81 years]) with gastrointestinal basidiobolomycosis, most were from the United States (19 patients [43%], of whom 17 [89%] were from Arizona) or Saudi Arabia (11 [25%]). Most (28 [64%]) were previously healthy. Common chronic medical conditions among 15 patients (34%) were diabetes mellitus (8 patients [18%]) and gastric disorders (7 [16%]). Common findings were abdominal pain (37 patients [84%]) and a palpable abdominal mass (19 [43%]). Intraabdominal malignancy was the leading provisional diagnosis (19 patients [43%]). The large bowel was involved in 36 (82%), the small intestine in 16 (36%), and the liver or gallbladder in 13 (30%). Characteristic histopathologic findings were observed in 43 (98%). Eight patients (18%) died. Combined surgical intervention and antifungal therapy was the preferred treatment.Conclusions.Gastrointestinal basidiobolomycosis is an emerging invasive fungal infection in desert regions of the US Southwest. Clinical findings mimic malignancy and inflammatory bowel disease. Surgical excision and prolonged antifungal therapy are associated with favorable outcomes.

Original languageEnglish (US)
Pages (from-to)1685-1691
Number of pages7
JournalClinical Infectious Diseases
Volume54
Issue number12
DOIs
StatePublished - Jun 15 2012

Fingerprint

Entomophthorales
Southwestern United States
Mycoses
Saudi Arabia
Centers for Disease Control and Prevention (U.S.)
Gallbladder
Inflammatory Bowel Diseases
Abdominal Pain
Small Intestine
Health Services
Medical Records
Observational Studies
Communicable Diseases
Neoplasms
Stomach
Diabetes Mellitus
Epidemiology
Cohort Studies
Therapeutics
Pathology

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Emergence of Gastrointestinal Basidiobolomycosis in the United States, with a Review of Worldwide Cases. / Vikram, Holenarasipur R.; Smilack, Jerry D.; Leighton, Jonathan A; Crowell, Michael D.; De Petris, Giovanni.

In: Clinical Infectious Diseases, Vol. 54, No. 12, 15.06.2012, p. 1685-1691.

Research output: Contribution to journalArticle

Vikram, Holenarasipur R. ; Smilack, Jerry D. ; Leighton, Jonathan A ; Crowell, Michael D. ; De Petris, Giovanni. / Emergence of Gastrointestinal Basidiobolomycosis in the United States, with a Review of Worldwide Cases. In: Clinical Infectious Diseases. 2012 ; Vol. 54, No. 12. pp. 1685-1691.
@article{99febd06a2b248f6a0961c26b8e12135,
title = "Emergence of Gastrointestinal Basidiobolomycosis in the United States, with a Review of Worldwide Cases",
abstract = "Background. We examined the epidemiology, clinical manifestations, histopathology, management, and outcomes of gastrointestinal basidiobolomycosis, an uncommon manifestation of infection caused by the fungus Basidiobolus ranarum.Methods.In this retrospective observational cohort study, cases of gastrointestinal basidiobolomycosis in the United States were identified by reviewing medical records from Mayo Clinic Hospital (Phoenix, AZ) and contacting local infectious diseases specialists, pathologists, gastroenterologists, the Arizona Department of Health Services, health departments of adjacent states, the Armed Forces Institute of Pathology, and the US Centers for Disease Control and Prevention. A comprehensive literature review identified additional cases worldwide.Results.Of 44 patients (mean age, 37 years [range, 2-81 years]) with gastrointestinal basidiobolomycosis, most were from the United States (19 patients [43{\%}], of whom 17 [89{\%}] were from Arizona) or Saudi Arabia (11 [25{\%}]). Most (28 [64{\%}]) were previously healthy. Common chronic medical conditions among 15 patients (34{\%}) were diabetes mellitus (8 patients [18{\%}]) and gastric disorders (7 [16{\%}]). Common findings were abdominal pain (37 patients [84{\%}]) and a palpable abdominal mass (19 [43{\%}]). Intraabdominal malignancy was the leading provisional diagnosis (19 patients [43{\%}]). The large bowel was involved in 36 (82{\%}), the small intestine in 16 (36{\%}), and the liver or gallbladder in 13 (30{\%}). Characteristic histopathologic findings were observed in 43 (98{\%}). Eight patients (18{\%}) died. Combined surgical intervention and antifungal therapy was the preferred treatment.Conclusions.Gastrointestinal basidiobolomycosis is an emerging invasive fungal infection in desert regions of the US Southwest. Clinical findings mimic malignancy and inflammatory bowel disease. Surgical excision and prolonged antifungal therapy are associated with favorable outcomes.",
author = "Vikram, {Holenarasipur R.} and Smilack, {Jerry D.} and Leighton, {Jonathan A} and Crowell, {Michael D.} and {De Petris}, Giovanni",
year = "2012",
month = "6",
day = "15",
doi = "10.1093/cid/cis250",
language = "English (US)",
volume = "54",
pages = "1685--1691",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Emergence of Gastrointestinal Basidiobolomycosis in the United States, with a Review of Worldwide Cases

AU - Vikram, Holenarasipur R.

AU - Smilack, Jerry D.

AU - Leighton, Jonathan A

AU - Crowell, Michael D.

AU - De Petris, Giovanni

PY - 2012/6/15

Y1 - 2012/6/15

N2 - Background. We examined the epidemiology, clinical manifestations, histopathology, management, and outcomes of gastrointestinal basidiobolomycosis, an uncommon manifestation of infection caused by the fungus Basidiobolus ranarum.Methods.In this retrospective observational cohort study, cases of gastrointestinal basidiobolomycosis in the United States were identified by reviewing medical records from Mayo Clinic Hospital (Phoenix, AZ) and contacting local infectious diseases specialists, pathologists, gastroenterologists, the Arizona Department of Health Services, health departments of adjacent states, the Armed Forces Institute of Pathology, and the US Centers for Disease Control and Prevention. A comprehensive literature review identified additional cases worldwide.Results.Of 44 patients (mean age, 37 years [range, 2-81 years]) with gastrointestinal basidiobolomycosis, most were from the United States (19 patients [43%], of whom 17 [89%] were from Arizona) or Saudi Arabia (11 [25%]). Most (28 [64%]) were previously healthy. Common chronic medical conditions among 15 patients (34%) were diabetes mellitus (8 patients [18%]) and gastric disorders (7 [16%]). Common findings were abdominal pain (37 patients [84%]) and a palpable abdominal mass (19 [43%]). Intraabdominal malignancy was the leading provisional diagnosis (19 patients [43%]). The large bowel was involved in 36 (82%), the small intestine in 16 (36%), and the liver or gallbladder in 13 (30%). Characteristic histopathologic findings were observed in 43 (98%). Eight patients (18%) died. Combined surgical intervention and antifungal therapy was the preferred treatment.Conclusions.Gastrointestinal basidiobolomycosis is an emerging invasive fungal infection in desert regions of the US Southwest. Clinical findings mimic malignancy and inflammatory bowel disease. Surgical excision and prolonged antifungal therapy are associated with favorable outcomes.

AB - Background. We examined the epidemiology, clinical manifestations, histopathology, management, and outcomes of gastrointestinal basidiobolomycosis, an uncommon manifestation of infection caused by the fungus Basidiobolus ranarum.Methods.In this retrospective observational cohort study, cases of gastrointestinal basidiobolomycosis in the United States were identified by reviewing medical records from Mayo Clinic Hospital (Phoenix, AZ) and contacting local infectious diseases specialists, pathologists, gastroenterologists, the Arizona Department of Health Services, health departments of adjacent states, the Armed Forces Institute of Pathology, and the US Centers for Disease Control and Prevention. A comprehensive literature review identified additional cases worldwide.Results.Of 44 patients (mean age, 37 years [range, 2-81 years]) with gastrointestinal basidiobolomycosis, most were from the United States (19 patients [43%], of whom 17 [89%] were from Arizona) or Saudi Arabia (11 [25%]). Most (28 [64%]) were previously healthy. Common chronic medical conditions among 15 patients (34%) were diabetes mellitus (8 patients [18%]) and gastric disorders (7 [16%]). Common findings were abdominal pain (37 patients [84%]) and a palpable abdominal mass (19 [43%]). Intraabdominal malignancy was the leading provisional diagnosis (19 patients [43%]). The large bowel was involved in 36 (82%), the small intestine in 16 (36%), and the liver or gallbladder in 13 (30%). Characteristic histopathologic findings were observed in 43 (98%). Eight patients (18%) died. Combined surgical intervention and antifungal therapy was the preferred treatment.Conclusions.Gastrointestinal basidiobolomycosis is an emerging invasive fungal infection in desert regions of the US Southwest. Clinical findings mimic malignancy and inflammatory bowel disease. Surgical excision and prolonged antifungal therapy are associated with favorable outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84861490495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861490495&partnerID=8YFLogxK

U2 - 10.1093/cid/cis250

DO - 10.1093/cid/cis250

M3 - Article

C2 - 22441651

AN - SCOPUS:84861490495

VL - 54

SP - 1685

EP - 1691

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 12

ER -